P0038 - Bone Metastasis Is Associated with Poor Survival Outcomes in Gall Bladder Adenocarcinoma

Kriti Gera, MD¹, Diana N. Rodriguez, MD², Daniela Martir, MD², Zohaib Ijaz, MD², Ilyas Sahin, MD^3
1UF Health Shands Hospital, Gainesville, FL; ²University of Florida, Gainesville, FL; ³University of Florida Shands, Gainesville, FL

Introduction: With the increasing incidence of advanced stage gallbladder adenocarcinoma, several studies have been conducted to understand the management and outcomes. However, there is paucity of data on site-specific metastasis. Bone is a rare site of metastasis in gallbladder adenocarcinoma and prognostic significance of this manifestation is unclear.

Methods: We performed a retrospective analysis of the Surveillance Epidemiology and End Results (SEER) database, a U.S. population-based registry maintained by National Cancer Institute. All cases with histologically confirmed diagnosis of gallbladder adenocarcinoma during the period of 2018-20 who were at American Joint Committee on Cancer (AJCC) M1 stage were included in the study. They were divided into two groups based on if they were treated with chemotherapy. Overall survival (OS) was estimated using Kaplan Meier method. Survival between groups was compared using log-rank test.

Results: 933 patients satisfied the inclusion criteria and were included in the analysis. 68% were female and 72% were white. Median age was 69 (24-90+) years. 7.2% (n=68) patients presented with bone metastasis on diagnosis. Out of the 68 patients, 4, 26, 23 and 24 also had brain, lung, liver and distant nodal metastasis respectively. 56% (n=530) received chemotherapy treatment. In the treatment group, median OS for patients with and without bone metastasis was 5 and 8 months respectively (p=0.036). Among patients who did not receive treatment, median OS for both groups with and without bone metastasis was 1 month (p=0.55).

Discussion: Gallbladder cancer with bone metastasis continues to have dismal prognosis, but treatment interventions can help extend survival. However, the survival outcomes for patients with bone metastasis are significantly worse compared to those with metastasis in other organs, despite receiving treatment.



Disclosures:


Kriti Gera, MD¹, Diana N. Rodriguez, MD², Daniela Martir, MD², Zohaib Ijaz, MD², Ilyas Sahin, MD³. P0038 - Bone Metastasis Is Associated with Poor Survival Outcomes in Gall Bladder Adenocarcinoma, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.